News

Hurdles include limited space, handling thin sclera, choosing the right site.

The sharing of data between ophthalmologists and optometrists ultimately can lead to earlier diagnosis and better results for patients.

PBM treatment showed a statistically significant slowing of disease progression in patients with early to intermediate dry AMD.

PBM treatment showed a statistically significant slowing of disease progression in patients with early to intermediate dry AMD.

Procedure integrates femto, phaco in one instrument to address issues.

The findings have potential clinical and public health implications and highlight the greater role of metabolic health status than obesity in IOP elevation, according to the authors.

If approved, OCS-01 has the potential to become the first once-daily, topical, preservative-free corticosteroid for treating inflammation and pain following ocular surgery.

To support congressional action, 135 health organizations – including the American Academy of Ophthalmology – sent a letter to congressional leaders pointing out that a full inflation-based update is the primary solution to the ongoing problem with the Medicare Physician Fee Schedule.

To support congressional action, 135 health organizations – including the American Academy of Ophthalmology – sent a letter to congressional leaders pointing out that a full inflation-based update is the primary solution to the ongoing problem with the Medicare Physician Fee Schedule.

According to court records, Paul Wade Wyatt continued to perform ophthalmic procedures in Utah after his license had been suspended in October 2016.

Imaging biomarkers are useful to determine the degree of EZ attenuation in the fovea.

Look for fluctuating vision, test objectively and keep a few effective tools at your disposal to treat OSD.

Delegates will analyze the most relevant and controversial issues within the field of ophthalmology at this year’s congress in Lisbon, Portugal, from March 24 to 25.

Industry leaders look at what’s in the therapeutic delivery pipeline for these disorders.

Kamran M. Riaz, MD, a clinical associate professor and director of Medical Student Research at the Dean A. McGee Institute at the University of Oklahoma, recently discussed with Ophthalmology Times some of the latest trends in cornea treatment.

Cognition plans to initiate the Phase 2 MAGNIFY trial of its oral drug candidate, CT1812 in 2023 in individuals with dry AMD who have measurable GA.

The company’s MINIject is the only commercially available MIGS implant targeting the supraciliary space.

Data for IG-002 show for the first time that a single subretinal administration of a DNA payload encoding the human ABCA4 gene resulted in durable expression of human ABCA4 protein.

The results support plan to advance lead program in ABCA4-related retinopathies into the clinic in 2024 and expansion into other ophthalmology indications.

Physicians should consider hydrodynamic cavitation when performing this procedure.

Industry leaders view pegcetacoplan as most important retinal technology in 10 years.

Session moderators, speakers and audience members all will examine and analyse the most relevant and controversial issues within the field of ophthalmology.

This subtype of artificial intelligence technology may have long-range implications for clinical trials.